Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 0.51 |
| ▸ | DRD2 | P14416 | 9/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352994 | 1.00 | DRD4 (0.51) | DRD4DRD2DRD3NAMPTADRA1D | |
| SCHEMBL6353760 | 0.81 | DRD4 (0.76) | DRD4DRD2DRD3 | |
| SCHEMBL6353764 | 0.81 | DRD4 (0.76) | DRD4DRD2DRD3 | |
| SCHEMBL4003996 | 0.75 | DRD4 (0.69) | DRD4DRD2DRD3 | |
| SCHEMBL6211655 | 0.72 | DRD4 (0.66) | DRD4DRD2DRD3 | |
| SCHEMBL4004216 | 0.69 | DRD4 (0.63) | DRD4DRD2DRD3 | |
| SCHEMBL6350322 | 0.69 | DRD4 (0.84) | DRD4DRD2 | |
| SCHEMBL6350324 | 0.69 | DRD4 (0.84) | DRD4DRD2 | |
| SCHEMBL10819399 | 0.69 | DRD4 (0.54) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL4003191 | 0.69 | DRD4 (0.70) | DRD4DRD2DRD3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | claimed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885DRD2 1704/4885DRD3 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.